Regenetp (Regenetp) Momentum Rank : 0 (As of Jun. 02, 2024)

View and export this data going back to 1999. Start your Free Trial

What is Regenetp Momentum Rank?

Regenetp has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Regenetp Momentum Rank Related Terms

Thank you for viewing the detailed overview of Regenetp's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenetp (Regenetp) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (OTCPK:RGTPQ) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1960 South 4250 West, Salt Lake City, UT, USA, 84104

Website

https://www.polarityte.com

Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.

Executives

Peter A Cohen	director	40 WEST 57TH STREET, SUITE 2020, NEW YORK NY 10019
David B Seaburg	director	1960 S 4250 W, SALT LAKE CITY UT 84104
Richard Hague	officer: Chief Operating Officer	1960 S 4250 W, SALT LAKE CITY UT 84104
Cameron J. Hoyler	other: General Counsel	1960 S 4250 W, SALT LAKE CITY UT 84104
Jeffrey Hansen Dyer	director	4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Jessica Xiaolin Shen	director	POLARITYTE, INC. (NASDAQ: PTE), 1960 S. 4250 WEST, SALT LAKE CITY UT 84104
Chris Nolet	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Paul Elliot Mann	officer: Chief Financial Officer	C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Jacob Alexander Patterson	officer: Chief Financial Officer	14822 S. ROSESCAPE CIRCLE, HERRIMAN UT 84096
Denver Lough	10 percent owner, other: Prior D&O within 90 days	4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Rainer M Erdtmann	director	1073 ARLINGTON BLVD., EL CERRITO CA 94530
Edward Winslow Swanson	director, officer: Chief Operating Officer	181 DANTE AVE., TUCKAHOE NY 07070
Steve Gorlin	director	150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Willie C Bogan	director	1943, ROSECREST DRIVE, OAKLAND CA 94602